Fox Chase Cancer Center

Oncobiologics, Fox Chase Cancer Center to create cancer therapy platform

Monday, August 22, 2011

Oncobiologics and Fox Chase Cancer Center have agreed to co-develop a novel, next-generation bi-specific antibody cancer platform with enhanced therapeutic capabilities against solid tumors. The jointly engineered platform is designed to handle multiple targets, representing a pipeline of promising cancer treatments. This research program is now underway, with preclinical studies expected in Q1-2012 for the first molecule using this platform.

[Read More]